13,475 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by CWA Asset Management Group LLC

CWA Asset Management Group LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,475 shares of the biopharmaceutical company’s stock, valued at approximately $907,000.

Several other large investors have also modified their holdings of HALO. DLD Asset Management LP purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth approximately $650,250,000. Arrowstreet Capital Limited Partnership boosted its holdings in Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after acquiring an additional 1,425,674 shares during the period. Federated Hermes Inc. boosted its holdings in Halozyme Therapeutics by 294.1% during the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after acquiring an additional 1,082,638 shares during the period. Voloridge Investment Management LLC bought a new position in Halozyme Therapeutics in the 3rd quarter valued at $77,587,000. Finally, Qube Research & Technologies Ltd bought a new position in Halozyme Therapeutics in the 2nd quarter valued at $51,295,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $62.86 on Tuesday. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The stock has a fifty day simple moving average of $71.34 and a two-hundred day simple moving average of $70.09. The stock has a market capitalization of $7.42 billion, a price-to-earnings ratio of 25.24, a P/E/G ratio of 0.26 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter in the prior year, the business posted $1.26 EPS. The business’s quarterly revenue was up 51.6% on a year-over-year basis. On average, analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Finally, Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $78.56.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 90,857 shares of company stock valued at $6,500,287. Company insiders own 2.90% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.